Amelioration of antitumour drug toxicity.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008081:Liposomes / Q000008:administration & dosage; D008727:Methotrexate / Q000009:adverse effects; D011658:Pulmonary Fibrosis / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D000932:Antiemetics; D000970:Antineoplastic Agents; D005609:Free Radicals; D008081:Liposomes; D001761:Bleomycin; D002955:Leucovorin; D008727:Methotrexate